Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Leukemia and Lymphoma With Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22

NCT03398967 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT03398967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03398967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Leukemia and Lymphoma With Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 2, 2018
Completion date
May 20, 2022
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell leukemia, b cell lymphoma